CD33 and acute myeloid leukemia: Having established that CD37 is broadly expressed in AML blast cells, we evaluate the potency of CD37CAR T cells against AML, comparing it to anti-CD19 fmc63-based CAR (CD19CAR) as a negative control and to anti-CD33 gemtuzumab ozogamicin-based CAR,11 CD33CAR, as a validated anti-AML CAR (Figure 2A).